Recommendation: Buy
| Entry Date | Symbol | Recommendation | Entry Price (USD) | Target 1 (USD) | Target 2 (USD) | Holding Duration | Position Status | Return(%)* |
|---|---|---|---|---|---|---|---|---|
| 5 Sep, 25 | CGTX | Buy | USD 2.59 | USD 2.72 | USD 2.85 | 10 days | Closed |
12.74%
|
*Return(%) represent the percentage change between the entry price and exit price of the recommendation.
Data Powered by EOD Historical Data (“EODHD”).
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.
Reduced Net Loss: Net loss decreased from USD 7.0 million in Q2 FY24 to USD 6.7 million in Q2 FY25, reflecting a modest improvement in financial performance
Lower G&A Expenses: General and administrative expenses fell from USD 3.1 million in Q2 FY24 to USD 2.5 million in Q2 FY25, a 19% reduction, driven primarily by lower stock-based compensation
Cash Position Constraint: As of June 30, 2025, the company held USD 11.6 million in cash (excluding USD 41.9 million in obligated grant funds), providing runway only until Q2 2026, which underscores dependency on external funding sources
Minimal R&D Expense Reduction: Research and development expenses decreased only marginally from USD 11.6 million in Q2 FY24 to USD 11.5 million in Q2 FY25, indicating limited cost efficiency in the company’s largest spending area
Cognition Therapeutics faces significant risk from its reliance on a single lead drug candidate, zervimesine, where clinical, regulatory, or partnership setbacks could materially impact its financial stability and long-term viability
| Entry Price | Support* | Target 1** | Target 2** |
|---|---|---|---|
| 2.59 | 2.3 | 2.72 | 2.85 |
Data Source: REFINITIV, Analysis: StockNextt
*Support can be considered as an indicative stop-loss, and if prices move below that level on closing basis individuals may evaluate exiting the position depending on their risk appetite, previous holdings, and other factors considered. The support and resistance levels may need to be re-evaluated within 4-6 weeks’ time frame depending on the stock price movements from the date of recommendation on the stock.
**Target prices may vary by ±0.5% depending on market volatility.
Price Action Analysis (on the daily chart)
CGTX’s stock price held support at its key levels and closed near the session highs in the previous trading session, suggesting the possibility of further upward movement in the near term. A significant resistance level around USD 3.13 is approaching and could be tested within the next two to four weeks. If the price manages to break above USD 3.13, it may attract greater buying interest, potentially driving the stock to higher levels.
Technical Indicators Analysis (On the daily chart)
On the daily chart, the 14-period Relative Strength Index (RSI) is trending upward, signaling increasing buying momentum at lower levels. Additionally, the price is trading above its key trend-following indicators—the 21-day and 50-day simple moving averages (SMAs)—which could act as immediate support levels in the near term.
As per the above-mentioned price action and technical indicators analysis, Cognition Therapeutics Inc. (NASDAQ: CGTX) is looking technically well-placed on the chart, and a ‘Buy’ recommendation has been given on the stock at the closing price of USD 2.59 as on 04 September 2025..
Data Powered by EOD Historical Data (“EODHD”).
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
|---|---|---|---|---|---|---|---|---|
| CGTX Cognition Therapeutics Inc |
-0.0199 1.31% | 1.50 | - | - | - | 1.22 | -0.4433 | |
| NVO Novo Nordisk A/S |
-0.8239 1.68% | 48.14 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-0.63 1.29% | 48.19 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-3.955 0.87% | 451.00 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
0.94 0.13% | 747.30 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Data Powered by EOD Historical Data (“EODHD”).
Related Risks: This report may be looked at from high-risk perspective and recommendations are provided are for a short duration. Recommendations provided in this report are solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc.
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is September 04,2025. The reference data in this report has been partly sourced from REFINITIV.
Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.
Target: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Target 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Target 2 may act as the crucial resistance level for the stock.
Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.
Disclaimer :
This report has been issued by StockNextt which has an Ontario Business Identification Number 1000958347 and British Columbia registration Number FM1051529 is a trade name under Kalkine Canada Advisory Services Inc. having Business Number 761925130BC0001. Kalkine Canada Advisory Services Inc. and StockNextt are collectively referred to as “StockNextt”, “we”, “us”, and “our”. The website https://stocknextt.com and associated pages are published by StockNextt. The information in this report and on the StockNextt website has been prepared from a wide variety of sources, which StockNextt, to the best of its knowledge and belief, considers accurate. StcokNextt has made every effort to ensure the reliability of information contained in its reports, newsletters, and websites. All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations for investing in securities and other financial products. StockNextt does not offer financial advice based upon your personal financial situation or goals, and we shall not be held liable for any investment or trading losses you may incur by using the opinions expressed in our reports, publications, market updates, news alerts and corporate profiles. StockNextt does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. StockNextt’s general advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested. Please also read our Terms and conditions for further information. Employees and/or associates of StockNextt and its related entities may hold an interest in the securities or other financial products covered in this report or on the StockNextt website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Copyright © 2023 Krish Capital Pty Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.
